Zebrafish Avatars for Colon Cancer Treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial uses tiny zebrafish to grow a piece of your tumor and test which treatments might work best for you. It is for patients with colon cancer who are scheduled for surgery to remove their tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer.
- You are planning to have surgery to remove the tumor.
- You are willing to sign a consent form.
- You are willing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a treatment plan that alternates two cancer pills and adds bevacizumab (a blood-vessel drug) for metastatic colon cancer that has come back or worsened after standard treatment. It may help shrink tumors and slow disease growth after later-line therapy options.
This trial tests a combination of two medications, fruquintinib (a targeted drug that stops blood vessel growth) and a chemotherapy pill called tegafur/gimeracil/oteracil (often used after standard chemo has stopped helping). The goal is to see if this combination can help control advanced colorectal cancer that has not responded to at least two prior treatments.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink colon cancer and improve outcomes. It is for people with a specific type of colon cancer that is planned for surgery.
This trial is testing a new drug (zanzalintinib) alone or with pembrolizumab to see if it can stop cancer from coming back in people with colorectal cancer who have no visible cancer on scans but still have tumor DNA in their blood.
This trial combines a new drug called ZEN003694 with two standard chemotherapy drugs (cetuximab and encorafenib) to see if it can help people with a specific type of colorectal cancer that has the BRAF V600E mutation. This mutation makes the cancer grow, and the new drug targets it, potentially making the treatment more effective.
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.